Sg Americas Securities, LLC Akebia Therapeutics, Inc. Transaction History

Sg Americas Securities, LLC

  • $78.3 Billion
  • Q4 2025

A detailed history of Sg Americas Securities, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 173,501 shares of AKBA stock, worth $294,951. This represents 0.0% of its overall portfolio holdings.

Number of Shares
173,501
Previous 116,393 49.06%
Holding current value
$294,951
Previous $318,000 12.26%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 09, 2026
BUY
$1.67 - $3.17 $95,370 - $181,032
57,108 Added 49.06%
173,501 $279,000
Q3 2025

Oct 23, 2025
BUY
$2.7 - $4.01 $314,261 - $466,735
116,393 New
116,393 $318,000
Q1 2025

Apr 15, 2025
SELL
$1.69 - $2.84 $46,894 - $78,804
-27,748 Reduced 23.76%
89,023 $171,000
Q4 2024

Jan 17, 2025
BUY
$1.26 - $2.13 $56,455 - $95,436
44,806 Added 62.26%
116,771 $222,000
Q3 2024

Oct 03, 2024
BUY
$0.94 - $1.55 $36,491 - $60,172
38,821 Added 117.13%
71,965 $95,000
Q2 2024

Jul 12, 2024
BUY
$0.86 - $1.63 $28,503 - $54,024
33,144 New
33,144 $34,000
Q1 2022

Apr 29, 2022
SELL
$0.72 - $2.93 $31,086 - $126,505
-43,176 Closed
0 $0
Q4 2021

Feb 07, 2022
SELL
$2.26 - $3.34 $153,869 - $227,400
-68,084 Reduced 61.19%
43,176 $98,000
Q3 2021

Nov 01, 2021
BUY
$2.35 - $3.88 $231,294 - $381,881
98,423 Added 766.71%
111,260 $320,000
Q2 2021

Aug 12, 2021
SELL
$2.83 - $4.2 $51,166 - $75,936
-18,080 Reduced 58.48%
12,837 $49,000
Q1 2021

May 13, 2021
BUY
$2.92 - $5.06 $36,269 - $62,850
12,421 Added 67.16%
30,917 $105,000
Q4 2020

Feb 04, 2021
SELL
$2.22 - $3.78 $475,892 - $810,303
-214,366 Reduced 92.06%
18,496 $52,000
Q3 2020

Nov 09, 2020
BUY
$2.39 - $13.08 $427,133 - $2.34 Million
178,717 Added 330.07%
232,862 $584,000
Q2 2020

Jul 20, 2020
BUY
$6.67 - $13.58 $128,564 - $261,754
19,275 Added 55.28%
54,145 $735,000
Q1 2020

Apr 30, 2020
BUY
$4.1 - $10.24 $39,909 - $99,676
9,734 Added 38.73%
34,870 $264,000
Q4 2019

Jan 28, 2020
BUY
$3.16 - $6.73 $33,729 - $71,836
10,674 Added 73.81%
25,136 $159,000
Q3 2019

Nov 04, 2019
BUY
$3.55 - $5.4 $51,340 - $78,094
14,462 New
14,462 $57,000
Q2 2019

Jul 29, 2019
SELL
$4.1 - $8.05 $109,867 - $215,715
-26,797 Closed
0 $0
Q1 2019

Apr 29, 2019
SELL
$5.41 - $8.73 $282,548 - $455,941
-52,227 Reduced 66.09%
26,797 $219,000
Q4 2018

Feb 01, 2019
SELL
$5.39 - $9.15 $3,260 - $5,535
-605 Reduced 0.76%
79,024 $437,000
Q3 2018

Nov 06, 2018
BUY
$7.44 - $10.65 $592,439 - $848,048
79,629 New
79,629 $703,000
Q4 2017

Jan 24, 2018
SELL
$14.24 - $19.59 $123,176 - $169,453
-8,650 Closed
0 $0
Q3 2017

Nov 07, 2017
BUY
$13.06 - $19.67 $112,969 - $170,145
8,650
8,650 $170,000

Others Institutions Holding AKBA

# of Institutions
190
Shares Held
121M
Call Options Held
267K
Put Options Held
280K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $313M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email